View Older Stories View More Recent Stories

Jun 1, 2020 08:30AM Resverlogix Plans COVID-19 Clinical Trial Program Launch
Mar 31, 2020 08:00AM Resverlogix Announces Participation at the American College of Cardiology Scientific Sessions together with the World Congress of Cardiology Virtual
Mar 30, 2020 08:00AM Resverlogix Announces Publication of Key Apabetalone Study BETonMACE in the Journal of the American Medical Association
Mar 24, 2020 08:00AM Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
Mar 23, 2020 07:00AM Resverlogix Invites Collaborations for use of Apabetalone in Trials and Studies to Combat the Spread of COVID-19 Based on New Research
Feb 3, 2020 07:30AM Resverlogix Receives US FDA Breakthrough Therapy Designation for Apabetalone
Feb 3, 2020 07:30AM Resverlogix Receives US FDA Breakthrough Therapy Designation for Apabetalone
Jan 13, 2020 09:17AM CORRECTION: Resverlogix Confirms a Significant Corporate Advancement Establishing Apabetalone as a Potential Blockbuster Combination Drug in High-risk Diabetes Patients with CVD
Jan 13, 2020 08:18AM Resverlogix Confirms a Significant Corporate Advancement Establishing Apabetalone as a Potential Blockbuster Combination Drug in High-risk Diabetes Patients with CVD
Dec 20, 2019 08:30AM Resverlogix Appoints Dicky To to its Board of Directors
Dec 11, 2019 08:30AM Resverlogix Announces Change to its Board of Directors
Dec 5, 2019 06:00PM Reminder: Resverlogix to Hold Conference Call and Webcast on December 6th, 2019
Dec 2, 2019 08:30AM Resverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019
Nov 25, 2019 06:00PM Resverlogix Announces Warrant Exercise Incentive Program
Nov 12, 2019 09:00AM Resverlogix to Hold BETonMACE Conference Call and Webcast on November 18, 2019
Oct 31, 2019 07:39PM Resverlogix Announces Voting Results from the 2019 Annual Meeting of Shareholders
Sep 30, 2019 07:30AM Resverlogix Announces Topline Results in BETonMACE Phase 3 Epigenetics Trial
Sep 27, 2019 09:27AM Resverlogix Announces US$12 Million Debenture Financing and Full Repayment of Loan
Sep 26, 2019 07:04PM Resverlogix to Host BETonMACE Webcast and Conference Call
Sep 23, 2019 08:30AM Resverlogix Announces BETonMACE Trial Results Accepted for Presentation at American Heart Association’s Scientific Sessions 2019
Sep 16, 2019 08:30AM Resverlogix Provides Update on BETonMACE Phase 3 Trial
Aug 22, 2019 05:24PM Resverlogix Announces Annual and Special Meeting of Shareholders
Aug 14, 2019 08:30AM Resverlogix to Present at the European Society of Cardiology’s ESC Congress 2019
Aug 2, 2019 12:02PM Resverlogix Announces Loan Reduction and Extension
Jul 15, 2019 08:30AM Resverlogix Announces Publication on Apabetalone in Clinical Epigenetics
Jul 8, 2019 08:30AM Resverlogix’s BETonMACE Phase 3 Epigenetics Trial Completes Final Safety Visits
Jun 12, 2019 08:30AM Resverlogix Provides Update on BETonMACE Phase 3 Epigenetics Trial
Jun 10, 2019 08:30AM Resverlogix Announces Participation at Leading, International Scientific Conferences
May 6, 2019 08:30AM Resverlogix Announces Publication on Apabetalone in High-Impact American Journal of Respiratory and Critical Care Medicine (AJRCCM)
May 2, 2019 05:12PM Resverlogix Announces 3-Month Loan Extension
Apr 18, 2019 08:00AM Resverlogix’ BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE Events
Apr 1, 2019 11:00AM Resverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International Conference on Alzheimer’s & Parkinson’s Diseases
Apr 1, 2019 08:00AM Resverlogix Announces $15.1 Million of Private Placements
Mar 27, 2019 12:06PM Resverlogix Announces Ninth Positive Data Safety Monitoring Board Recommendation for Phase 3 Study of Apabetalone
Mar 18, 2019 12:00PM Resverlogix Proudly Announces Funding for Phase 2 Trial Evaluating Apabetalone in Pulmonary Arterial Hypertension Led by Quebec Heart and Lung Institute – Laval University Researcher
Mar 11, 2019 05:00AM Resverlogix Announces Participation at Prominent Industry and Investor Conferences
Jan 31, 2019 06:00PM Resverlogix Closes $6.6 Million Private Placement with Shenzhen Hepalink
Dec 19, 2018 08:30AM Resverlogix Announces Eighth Positive Data Safety Monitoring Board Recommendation For Phase 3 Study of Apabetalone
Nov 28, 2018 08:30AM Resverlogix Announces Publication on Apabetalone in Atherosclerosis Journal
Nov 2, 2018 04:05PM Resverlogix Closes $13.5 Million Private Placement
Oct 22, 2018 08:30AM Resverlogix Announces Participation at Premier Kidney, Alzheimer’s Disease and Cardiovascular Conferences
Sep 12, 2018 06:30PM Resverlogix Announces Voting Results from the 2018 Annual and Special Meeting of Shareholders
Sep 4, 2018 08:00AM Resverlogix Presents at Clinical Trials in Alzheimer’s Disease (CTAD) Asia 2018
Aug 30, 2018 08:00AM Resverlogix Announces $26 Million Private Placement
Aug 22, 2018 07:00AM Resverlogix Supports Epigenetics Satellite Symposium and Provides Oral Presentation on Apabetalone at the European Society of Cardiology Congress 2018 in Munich
Aug 7, 2018 07:00AM Resverlogix Announces Seventh Positive Recommendation From The Data Safety Monitoring Board For Phase 3 Study of Apabetalone
Jul 31, 2018 05:00PM Resverlogix Intends to Pursue U.S. Listing
Jul 17, 2018 07:00AM Resverlogix Announces Upcoming Presentations at Clinical Trials in Alzheimer’s Disease (CTAD) Asia and Alzheimer’s Association International Conference (AAIC)
Jun 14, 2018 03:20PM Resverlogix Announces FDA Confirmation Regarding Filing Pathway for Apabetalone
Jun 7, 2018 07:00AM Resverlogix Highlights Potential to Develop Apabetalone as a Therapeutic for HIV-1 Eradication Utilizing the “Shock and Kill” Approach
View More Recent Stories View Older Stories